Corporate Profile

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Change

Minimum 15 minutes delayed. Source: LSEG

News Releases

Dec 16
2024
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Learn More >
Dec 12
2024
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Learn More >
Nov 19
2024
Allogene Therapeutics Announces Participation in December Investor Conferences
Learn More >
Nov 18
2024
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
Learn More >
Nov 07
2024
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
Learn More >
Nov 07
2024
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
Learn More >
Nov 05
2024
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
Learn More >
Nov 04
2024
Allogene Therapeutics Announces Participation in November Investor Conferences
Learn More >
Oct 30
2024
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
Learn More >
Oct 29
2024
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Learn More >
View All